Metronidazole, ranitidine and clarithromycin combination for treatment of Helicobacter pylori infection (modified Bazzoli's triple therapy)

Background: Multi‐drug regimens are generally required to reliably cure Helicobarter pylori infection. Metronidazole, clarithromycin and omeprazole has proven to be an effective combination therapy with a cure rate of 90% or greater.

[1]  R. Genta,et al.  Metronidazole, omeprazole and clarithromycin: an effective combination therapy for Helicobacter pylori infection , 1995, Alimentary pharmacology & therapeutics.

[2]  W. Opferkuch,et al.  Modified short-term triple therapy--ranitidine, clarithromycin, and metronidazole--for cure of Helicobacter pylori infection. , 1995, The American journal of gastroenterology.

[3]  F. Bazzoli,et al.  Short‐term low‐dose triple therapy for the eradication of Helicobacter pylori , 1994 .

[4]  D. Graham,et al.  Benefits from elimination of Helicobacter pylori infection include major reduction in the incidence of peptic ulcer disease, gastric cancer, and primary gastric lymphoma. , 1994, Preventive medicine.

[5]  D. Graham,et al.  Helicobacter pylori: consensus reached: peptic ulcer is on the way to becoming an historic disease. , 1994, The American journal of gastroenterology.

[6]  Fred E. Silverstein,et al.  Helicobacter pylori in peptic ulcer disease. , 1994, NIH consensus statement.

[7]  D. Graham,et al.  Simultaneous visualization of Helicobacter pylori and gastric morphology: a new stain. , 1994, Human pathology.

[8]  Rune Sj.  Treatment strategies for symptom resolution, healing, and Helicobacter pylori eradication in duodenal ulcer patients. , 1994 .

[9]  C. O'Morain,et al.  Prevalence of metronidazole-resistant helicobacter pylori in dyspeptic patients , 1993, Irish journal of medical science.

[10]  D. Graham,et al.  THE ROLE OF INFECTIOUS AGENTS IN PEPTIC ULCER DISEASE , 1993 .

[11]  R. Greenberg,et al.  Helicobacter pylori and recurrence of duodenal ulcers. , 1992, The American journal of gastroenterology.

[12]  D. Peters,et al.  Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. , 1992, Drugs.

[13]  J. Weil,et al.  Helicobacter pylori and metronidazole resistance , 1990, The Lancet.

[14]  V. Alvisi,et al.  Sydney classification for gastritis and Helicobacter pylori , 1990, The Lancet.

[15]  A. Burette,et al.  Drug therapy for Helicobacter pylori infection: problems and pitfalls. , 1990, The American journal of gastroenterology.

[16]  A. Morden,et al.  Helicobacter pylori infection treated with a tripotassium dicitrato bismuthate and metronidazole combination , 1990, Alimentary pharmacology & therapeutics.

[17]  C. O'Morain,et al.  Adjuvant antibiotic therapy in duodenal ulcers treated with colloidal bismuth subcitrate. , 1990, Gut.

[18]  D. Vos,et al.  Metronidazole resistance in Helicobacter pylori , 1990, The Lancet.

[19]  A. Janssen,et al.  Metronidazole-resistant Helicobacter pylori , 1990, The Lancet.

[20]  K. Hanada,et al.  The Susceptibility of Campylobacter pylori to Antiulcer Agents and Antibiotics , 1990, Journal of clinical gastroenterology.

[21]  D. Graham,et al.  In vivo susceptibility of Campylobacter pylori. , 1989, The American journal of gastroenterology.

[22]  P. Fernandes,et al.  Susceptibility of Campylobacter pylori to macrolides and fluoroquinolones. , 1988, The Journal of antimicrobial chemotherapy.